# OnCo record rejuv-paed-heart (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-paed-heart/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-paed-heart" ;
  schema:name "The heart after anthracyclines and chest radiotherapy in childhood"@en ;
  schema:description "Heart damage from childhood treatment appears quietly and decades later. When 1,853 adult survivors were examined rather than asked, 7.4 per cent had cardiomyopathy and 28 per cent had valve disease, and most of it was new at that visit: nearly all of them had no symptoms. High blood pressure multiplied the risk of heart failure nineteenfold, which makes it the most treatable thing on the page."@en ;
  schema:url <https://onco.cc/technologies/rejuv-paed-heart/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cardiomyopathy> ;
  schema:citation <https://doi.org/10.1136/bmj.b4606>, <https://doi.org/10.7326/M15-0424>, <https://doi.org/10.1200/JCO.2013.49.3205>, <https://doi.org/10.1016/S1470-2045(14)70409-7> ;
  onco:status "standard-of-care" ;
  onco:tag "rejuvenation", "survivorship", "paediatric", "late-effects", "evidence:strong" ;
  onco:related <https://onco.cc/trials/ccss/>, <https://onco.cc/collections/sjlife/>, <https://onco.cc/collections/ighg/>, <https://onco.cc/ideas/idea-moon-cardioprotection-by-default/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/aml-paediatric/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/wilms-tumor/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/>, <https://onco.cc/technologies/anthracycline-cardioprotection/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/strain-echocardiography-gls/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/>, <https://onco.cc/technologies/exercise-prescription-after-cancer/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/dexrazoxane/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .